Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19584869 | 0.84 | MEN1 (0.54) | MEN1KMT2APOLBNPSR1TPSAB1 | |
| SCHEMBL19609093 | 0.82 | ALDH1A1 (0.53) | POLBSMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL19609289 | 0.81 | ALDH1A1 (0.46) | KMT2APOLBTPSAB1TPSD1TPSG1 | |
| SCHEMBL12466228 | 0.80 | MEN1 (0.77) | MEN1KMT2APOLBNPSR1SMN1; SMN2 | |
| SCHEMBL19609684 | 0.80 | HRH1 (0.53) | MAPTLMNAALDH1A1 | |
| SCHEMBL12814093 | 0.80 | KDM4E (0.64) | MEN1KMT2ASMN1; SMN2MAPTHPGD | |
| SCHEMBL20236538 | 0.80 | ALDH1A1 (0.62) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL28642400 | 0.76 | UBE2M (0.43) | MEN1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL12813875 | 0.75 | KDM4E (0.58) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7134528 | 0.75 | ALDH1A1 (0.58) | MEN1KMT2APOLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2022-09-08 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| CN-109153636-B | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | 朱比连特埃皮科尔有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | MEN1 3882/4885KMT2A 18/4885POLB 2299/4885 |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | MEN1 3882/4885KMT2A 18/4885POLB 2299/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | MEN1 4177/4885KMT2A 17/4885POLB 2099/4885 |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | MEN1 4177/4885KMT2A 17/4885POLB 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.